Masimo has been recognized as one of the 10 most innovative organizations in the North America sector.

IRVINE, California—Masimo (NASDAQ: MASI), a provider of noninvasive monitoring technologies and audio products, has announced its recognition as one of Fast Company’s Most Innovative Companies in North America for 2024. Masimo said this accolade is meaningful given its breakthroughs and its commitment to improving people’s lives through innovation.

“We are honored to be recognized by Fast Company as one of the top 10 Most Innovative Companies in North America for 2024,” said Joe Kiani, founder and CEO of Masimo. “This recognizes our ongoing commitment to driving innovation to improve lives. Since our founding 35 years ago, we have made solving what others thought unsolvable our task, and fortunately, thanks to our incredible team, we have solved many ‘unsolvable problems.’ Our solutions have helped improve patient care and reduce the cost of care. We intend to continue to innovate to usher in 22nd-century health care in this decade.”

Masimo has been recognized as one of the 10 most innovative organizations in the North America sector. In their announcement, Fast Company highlighted several Masimo breakthrough technologies that received FDA clearance in 2023, including Opioid Halo, an opioid overdose and prevention solution that is the first and only FDA-authorized device to alert you in the event of an opioid overdose; Stork, a baby monitor that provides continuous, accurate monitoring, with alarms, based on Masimo’s pulse oximetry technology; and Masimo W1, a first-of-its-kind wearable offering accurate, continuous health data and now available both in a consumer sport-oriented version and as a medical watch—the first FDA-cleared watch to provide continuous real-time oxygen saturation and pulse rate for over-the-counter and prescription use.

Today, Masimo’s portfolio encompasses a wide range of cutting-edge health care solutions, including its flagship Signal Extraction Technology (SET) pulse oximeter, Bridge for opioid withdrawal symptom relief, PerL with Masimo AAT for personalized listening and MightySat Medical, the first and only FDA-cleared medical fingertip pulse oximeter available over the counter. In addition, Masimo’s most recent consumer products, such as Masimo W1, Stork, and Opioid Halo, provide solutions for continuous and accurate data tracking so individuals can take better control of their health.

For more information about Masimo and its innovative solutions, please visit